A Phase 2 Study of Zelenectide Pevedotin in People With Advanced Breast Cancer

Full Title

Purpose

Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.

High levels of Nectin4 have been seen in some people with breast cancer. Zelenectide pevedotin is designed to target and kill tumor cells with a large amount of the Nectin4 protein. By targeting the Nectin4 protein, zelenectide pevedotin may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have hormone receptor-positive/HER2-negative or triple-negative breast cancer that came back, spread, or cannot be surgically removed.
• Have high levels of the Nectin4 gene in your tumor cells.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-5157.